Petefészekrák: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• BRCA1 20
• BRCA2 13
• PARP 27
• TP53 6
• PD-1 12
• AKT 2
• HER2 16
• PD-L1 7
• PI3K 3
• STAT3 1
• mTOR 0
• VEGF 7
• KRAS 6
• EGFR 3
• PTEN 2
• MAPK 0
• CTNNB1 0
• FAK 1
• MYC 0
• NRF2 0
• CTLA-4 6
• ERK 1
• JAK 0
• STING 0
• GPX4 0
• HIF-1 0
• MEK 1
• TROP2 4
• PALB2 5
• B7-H3 7
• CDK4/6 4
• ATM 1
• CD47 0
• IL-6 0
• PIK3CA 3
• EZH2 1
• JNK 0
• YAP 0
• BCL-2 0
• BRAF 4
• CXCR4 0
• HDAC 0
• PPAR 0
• AMPK 0
• ARID1A 3
• AXL 1
• COX-2 2
• NMDA 0
• TIGIT 0
• AR 0
• CD40 1
• HER3 1
• HMGB1 0
• KEAP1 1
• METTL3 0
• RAS 0
• TLR4 0
• FGFR 0
• PINK1 0
• PKM2 0

23+ intézményből 23, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NCI · F31

  The role of p16 expression in sensitivity and resistance to CDK2 inhibitors

  University of Colorado· Boulder, Egyesült Államok· 43 146 USD awarded in fiscal year 2026· until 2029. szept.

• NIH NIAID · R56

  Functional dissection of a novel E2 complex critical for the HPV16 life cycle

  Virginia Commonwealth University· Richmond, Egyesült Államok· 768 308 USD awarded in fiscal year 2026· until 2027. aug.

• NIH NCI · R01

  Overcoming ovarian cancer chemoresistance by co-targeting senescence and apoptosis

  Harvard University D/B/A Harvard School of Public Health· Boston, Egyesült Államok· 390 447 USD awarded in fiscal year 2026· until 2031. aug.

• NIH NCI · R01

  Immune Dysfunction, Social Determinants of Health, and Ovarian Cancer Outcome Differences

  University of Pittsburgh at Pittsburgh· Pittsburgh, Egyesült Államok· 674 142 USD awarded in fiscal year 2026· until 2031. aug.

• NIH NICHD · R61

  Ultrasound-guided Ovarian Tissue Graft generation Platform to improve fertility outcomes

  Atera Medical· Mountain View, Egyesült Államok· 377 257 USD awarded in fiscal year 2026· until 2028. jún.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Decoding the Lipidome of Adipose-Derived Extracellular Vesicles in Ovarian Cancer: Mechanistic Insight into Tumor-Adipose Crosstalk (Lipid-Ex)

  Philipps Universitaet Marburg· Marburg, Németország· EU contribution 202 125 EUR· until 2028. dec.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Precision Reasoning In Multimodal Ovarian cancer (PRIMO)

  Institut Regional du Cancer de Montpellier· Montpellier Cedex 5, Franciaország· EU contribution 150 000 EUR· until 2028. jún.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  CAR T ceLls with Anti-exhaUstion Device for Immunotherapy Advancement (CLAUDIA)

  Fondazione Istituto Italiano di Tecnologia· Genova, Olaszország· EU contribution 150 000 EUR· until 2028. márc.

• European Commission (Horizon Europe) · HORIZON-EIC

  Interpretable Multimodal Predictive Agents and Digital Twins for Ovarian Cancer (IMPACT-OC)

  Danube Private University Gmbh· Krems-Stein, Ausztria· EU contribution 3 977 586 EUR· until 2030. szept.· 5 countries

• European Commission (Horizon Europe) · HORIZON-RIA

  A Novel Phase-2a Clinical Trial for a Next-Generation Oncolytic Immunotherapy Targeting Platinum-Resistant Ovarian Cancer (OCTOPOD-Ph2a)

  Theolytics Ltd· Oxford, Egyesült Királyság· EU contribution 7 998 791 EUR· until 2029. máj.· 3 countries

10 of 669 running projects, newest first. Listed amounts together: 373,6 M USD + 54,2 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Leállították

  Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation

  NCT05523440· University of Oklahoma· Frissítve: 2026. jún. 3.

  “Funding issue”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer

  NCT05950464· National Cancer Institute (NCI)· Forrás

• A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

  NCT04104776· Novartis Pharmaceuticals· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 48
• Organoids 19
• Mendelian Randomization Analysis 30
• CRISPR-Cas Systems 15
• Gene Expression Profiling 126
• Sequence Analysis, RNA 11
• Whole Genome Sequencing 6
• Exome Sequencing 11
• Proteomics 62
• Metabolomics 17
• Mass Spectrometry 6
• Flow Cytometry 26
• Immunohistochemistry 95
• Liquid Biopsy 15
• Circulating Tumor DNA 14
• Xenograft Model Antitumor Assays 234
• Positron-Emission Tomography 9
• Magnetic Resonance Imaging 57
• Machine Learning 60
• Deep Learning 36
• Cohort Studies 105
• Genome-Wide Association Study 27

• Multi-omics analysis of high-grade serous ovarian cancers reveals heterogeneity and distinct immunological patterns based upon clinico-genomic status.

  PLoS Genet, 2026. okt.

• Clinical Utility of Germline Whole-Exome Sequencing Beyond Multigene Panels in Hereditary Cancer.

  Genes (Basel), 2026. szept.

• Multi-site sequencing supports dual-track evolution and identifies candidate metastasis-associated factors in gastric cancer ovarian metastasis.

  Clin Transl Med, 2026. szept.

• Whole-Exome Sequencing Identifies Candidate Genomic Features Associated with Response to Platinum-Based Chemotherapy and Ixabepilone-Based Treatment in Ovarian Cancer.

  Int J Mol Sci, 2026. aug.

• Comprehensive Germline Profiling of High-Grade Serous Ovarian Cancer Using Whole-Exome Sequencing.

  Int J Mol Sci, 2026. jún.

• CDHR2 c.2233C > T Is Involved in Human Familial Ovarian Immature Teratoma With BMP15 c.262C > T.

  Hum Mutat, 2026. jún.

• Mutational Signature-Based Biomarker for Phase II Trial of Olaparib Maintenance in Advanced High-Grade Ovarian Cancer.

  Cancer Sci, 2026. máj.

• Comprehensive molecular characterization identifies therapeutic vulnerabilities in ovarian clear cell carcinoma.

  Genome Med, 2026. máj.

• Molecular Profiling and Tumor Biomarker Analysis of GOG281/LOGS: A Positive Late-Phase Trial of Trametinib for Recurrent/Persistent Low-Grade Serous Ovarian Carcinoma.

  Clin Cancer Res, 2026. febr.

  Angeles Alvarez Secord

• Whole Exome Sequencing Revealed Rare Variants in BRCA2, RAD51D, FANGC, CYP24A1 Genes in Breast/Ovarian Cancer Patients from a Small Buryat Ethnic Group.

  Asian Pac J Cancer Prev, 2026. febr.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.